低分子肝素治疗性应用中抗Xa因子监测的系统综述
该系统综述纳入48项随机对照试验和观察性研究,评估抗Xa因子监测及据此调整剂量在低分子肝素治疗性应用中的有效性。主要结局为监测与未监测患者间大出血和静脉血栓栓塞症等临床事件的发生率。五项研究显示监测与未监测患者的出血和血栓栓塞并发症发生率相当,抗Xa因子水平与出血及血栓栓塞并发症的相关性即使存在也很弱。
要点
- 五项研究显示抗Xa因子监测与未监测患者的出血和血栓栓塞并发症发生率相当。
- 抗Xa因子水平测量与频繁的剂量调整相关。
- 抗Xa因子水平与出血及血栓栓塞并发症的相关性即使存在也很弱。
核心结论
- 本综述强调支持在低分子肝素治疗性应用中根据抗Xa因子监测调整剂量的证据有限。
- 作者结论认为目前测量抗Xa因子水平并不合理,只有新的高质量、最好为随机化的研究才能提供相反证据。
研究设计与样本
- 系统综述,纳入48项随机对照试验和观察性研究。
- 所有研究均存在高偏倚风险。
- 主要结局为监测与未监测抗Xa因子患者间大出血和静脉血栓栓塞症等临床事件的发生率。
- 次要结局为抗Xa因子水平与出血或血栓栓塞并发症的相关性,以及基于抗Xa因子水平的剂量调整频率。
主要发现
- 五项研究表明抗Xa因子监测与未监测患者的出血和血栓栓塞并发症发生率相当。
- 抗Xa因子水平测量与频繁的剂量调整相关。
- 抗Xa因子水平与出血及血栓栓塞并发症的相关性即使存在也很弱。
关键数值与推荐
- 原文未报告具体数值标准。
临床怎么用
- 作者结论认为目前测量抗Xa因子水平并不合理,只有新的高质量、最好为随机化的研究才能提供相反证据。
局限性
- 所有纳入研究均存在高偏倚风险。
- 作者结论认为只有新的高质量、最好为随机化的研究才能提供相反证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low-molecular-weight heparins are widely utilized, including in special patient populations (eg, patients with renal impairment, pregnancy, and obesity). Monitoring with anti-Xa measurements is often used, but the effectiveness of anti-Xa-based dose adjustments remains uncertain. This systematic review aimed to provide an informed assessment of the usefulness of anti-Xa monitoring and subsequent dose adjustments in these patients. The primary outcome was the incidence of clinical events, such as major bleeding and venous thromboembolism, compared between patients with and without anti-Xa monitoring. Secondary outcomes were the correlation between anti-Xa levels and bleeding or thromboembolic complications and the frequency of dose adjustments based on anti-Xa levels. A total of 48 studies, both randomized controlled trials and observational studies, were included. All studies had a high risk of bias. Five studies indicated comparable rates of bleeding and thromboembolic complications in anti-Xa-monitored and unmonitored patients. Measurement of anti-Xa levels was associated with frequent dose adjustments. The correlation between anti-Xa levels and both bleeding and thromboembolic complications was weak, if it was present at all. Overall, this review highlights the limited evidence supporting the use of anti-Xa monitoring for dose adjustments in the therapeutic use of low-molecular-weight heparins. Therefore, we conclude that measuring anti-Xa levels is currently not justified. Only new, high-quality, preferably randomized studies could indicate otherwise.
引用
- Jaspers TCC, Remmelzwaal PC, Weersink EPS, et al. A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins. J Thromb Haemost. 2025. PMID: 40617505. doi:10.1016/j.jtha.2025.06.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。